An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferon beta-1a (IFN beta-1a, Rebif) therapy in the induction of tolerance to IFN beta in MS patients with neutralising antibodies (NAbs) to subcutaneous IFN beta-1a (Rebif or Avonex).

Trial Profile

An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferon beta-1a (IFN beta-1a, Rebif) therapy in the induction of tolerance to IFN beta in MS patients with neutralising antibodies (NAbs) to subcutaneous IFN beta-1a (Rebif or Avonex).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Interferon beta-1a (Primary) ; Mitoxantrone (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top